Prulifloxacin versus Levofloxacin in the Treatment of Chronic Bacterial Prostatitis: a Prospective, Randomized, Double-Blind Trial

Ninety-six patients with chronic bacterial prostatitis (CBP) and evidence of infection were randomized to receive a 4-week oral course of either prulifloxacin (a new fluoroquinolone) 600 mg or levofloxacin 500 mg once daily. They were evaluated with the Meares-Stamey test and the National Institutes...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2007-06, Vol.19 (3), p.304-308
Main Authors: Giannarini, G., Mogorovich, A., Valent, F., Morelli, G., De Maria, M., Manassero, F., Barbone, F., Selli, C.
Format: Article
Language:English
Subjects:
Adult
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Chronic bacterial prostatitis
Chronic Disease
Dioxolanes - adverse effects
Dioxolanes - therapeutic use
Double-Blind Method
Fluoroquinolones - adverse effects
Fluoroquinolones - therapeutic use
Humans
Levofloxacin
Male
Meares-Stamey test
Medical sciences
Middle Aged
National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI)
Ofloxacin - adverse effects
Ofloxacin - therapeutic use
Pharmacology. Drug treatments
Piperazines - adverse effects
Piperazines - therapeutic use
Prospective Studies
prostatitis
Prostatitis - drug therapy
Prostatitis - microbiology
prulifloxacin
Quinolones - adverse effects
Quinolones - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ninety-six patients with chronic bacterial prostatitis (CBP) and evidence of infection were randomized to receive a 4-week oral course of either prulifloxacin (a new fluoroquinolone) 600 mg or levofloxacin 500 mg once daily. They were evaluated with the Meares-Stamey test and the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) at baseline and one week after therapy completion. Patients with microbiological eradication were evaluated again with the Meares-Stamey test 6 months after therapy completion. The microbiological eradication rate was 72.73% for prulifloxacin and 71.11% for levofloxacin (p=0.86) and the reduction in the NIH-CPSI was 10.75 and 10.73, respectively (p=0.98). Safety was comparable, with 18.18% adverse events for prulifloxacin and 22.22% for levofloxacin (p=0.79). Thus, a 4-week course of prulifloxacin 600 mg once daily is at least as effective and safe as levofloxacin 500 mg once daily in the treatment of CBP.
ISSN:1120-009X
1973-9478
DOI:10.1179/joc.2007.19.3.304